News Related to Primary IgA Nephropathy

Related coverage linked through entity extraction aliases.

Atrasentan and Obinutuzumab Show Promise for Rare Kidney Diseases in Phase 3 Trials

Feb 25, 2026

Phase 3 trials demonstrate atrasentan slows kidney function decline in IgA nephropathy patients, while obinutuzumab achieves superior remission rates in primary membranous nephropathy compared to standard treatment.

Novartis Vanrafia Phase III Data Show Slowing of Kidney Function Decline in IgA Nephropathy

Feb 13, 2026

Novartis announced final Phase III ALIGN results showing Vanrafia slowed kidney function decline in adults with IgA nephropathy, supporting planned submissions for traditional approval in 2026 following accelerated approvals in the U.S. and China in 2025.